Literature DB >> 29075910

Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab.

Anastasia Skalkou1, Sofia-Magdalini Manoli2, Alexandros Sachinidis1, Vasilios Ntouros3, Konstantinos Petidis1, Eleni Pagkopoulou4, Efstratios Vakirlis2, Athina Pyrpasopoulou1, Theodoros Dimitroulas5.   

Abstract

Rheumatoid arthritis is a systemic autoimmune disease resulting in joint destruction and deformities, but also associated with extraarticular and systemic manifestations. The later devastating conditions, such as the development of rheumatoid vasculitis, are more frequently encountered in seropositive patients and their incidence has been attenuated after the introduction of biologic disease modifying drugs, such as anti-tumor necrosis factor alpha (TNFa) agents, which generally have considerably contributed to the better control and long-term outcomes of the disease. Interestingly, autoimmune syndromes may, rarely, present in patients without a positive history after the initiation of treatment. We present a rare case of a woman with seronegative rheumatoid arthritis who developed pyoderma gangrenosum whistle on treatment with golimumab, a fully humanized anti TNFa antibody. The recording of this as well as analogous paradoxical autoimmune syndromes in association with the individual patient characteristics will render treating physicians aware of potential adverse reactions and assist in the understanding of the cytokine driven pathophysiological mechanisms underlying these disorders.

Entities:  

Keywords:  Anti-TNF-α; Golimumab; Pyoderma gangrenosum; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 29075910     DOI: 10.1007/s00296-017-3861-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Paradoxical reactions to targeted biological treatments: A way to treat and trigger?

Authors:  Alexandra M G Brunasso; Martin Laimer; Cesare Massone
Journal:  Acta Derm Venereol       Date:  2010-03       Impact factor: 4.437

2.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

3.  Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.

Authors:  Lutz Kowalzick; Julia Bertolini; Christine Baumann; Beate Walther; Beate Truhm; Lena Eickenscheidt
Journal:  J Dtsch Dermatol Ges       Date:  2013-01-23       Impact factor: 5.584

Review 4.  Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors.

Authors:  Armen Yuri Gasparyan; Lilit Ayvazyan; Heather Blackmore; George D Kitas
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

Review 5.  Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.

Authors:  Éric Toussirot; François Aubin
Journal:  RMD Open       Date:  2016-07-15

Review 6.  Drug-Induced Pyoderma Gangrenosum: A Review.

Authors:  Jane Y Wang; Lars E French; Neil H Shear; Afkham Amiri; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2018-02       Impact factor: 7.403

Review 7.  Pyoderma gangrenosum.

Authors:  Renu Saigal; Yadvinder Singh; Manoop Mittal; Amit Kansal; Hari Ram Maharia
Journal:  J Assoc Physicians India       Date:  2010-06

Review 8.  Anti-TNF therapy: past, present and future.

Authors:  Claudia Monaco; Jagdeep Nanchahal; Peter Taylor; Marc Feldmann
Journal:  Int Immunol       Date:  2014-11-19       Impact factor: 4.823

Review 9.  Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.

Authors:  Rafael Denadai; Fábio Vieira Teixeira; Flavio Steinwurz; Ricardo Romiti; Rogério Saad-Hossne
Journal:  J Crohns Colitis       Date:  2012-09-07       Impact factor: 9.071

10.  Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.

Authors:  Audrey S L Low; Deborah P M Symmons; Mark Lunt; Louise K Mercer; Chris P Gale; Kath D Watson; William G Dixon; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2017-01-10       Impact factor: 19.103

View more
  3 in total

1.  Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review.

Authors:  Anna Gawdzik; Małgorzata Ponikowska; Alina Jankowska-Konsur; Zdzisław Woźniak; Joanna Maj; Jacek C Szepietowski
Journal:  Dermatol Ther (Heidelb)       Date:  2020-05-23

2.  Pyoderma Gangrenosum After Insertion of a Hemodialysis Catheter: Koebner Phenomenon, Systemic Inflammatory Response Syndrome, and a Delay in Diagnosis.

Authors:  Majed M Alosaimi; Fatemah Sebzali; Ali Iqbal; Christian G Rabbat; Catherine M Clase
Journal:  Can J Kidney Health Dis       Date:  2022-09-20

Review 3.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.